NCT00612209View on ClinicalTrials.gov

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2010

Conditions
Cancer, Advanced Solid Tumors
Interventions
DRUG

ARQ 197

Treatment with ARQ 197

Trial Locations (1)

SM25PT

The Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00612209 - A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter